👤 Evan P Nadler

Metabolic and Bariatric Surgery (MBS) has evolved from being historically contraindicated for pediatric special needs populations to be an evidence-based standard of care. As obesity acts as a morbidity multiplier within this cohort, success with MBS is dependent on the strength of support ecosystems available to caregivers of these patients, rather than cognitive capacity. Although specific pathophysiology's such as intractable hyperphagia associated with Prader-Willi syndrome or complete MC4R deficiency may pose long-term durability challenges, many of these patients achieve weight loss and resolution of comorbidities comparable to their neurotypical peers. By applying a multidisciplinary ethical framework during the unique window of metabolic plasticity in children, clinicians can reverse life-threatening diseases prior to irreversible end organ damage occurs. This paradigm shift ensures that the most vulnerable patients are no longer denied transformative treatment based on underlying diagnoses alone. Show less

Melanocortin-4 receptor ( Pertinent details were derived from the electronic database among identified patients who had BS with MC4R-d (study group, SG) and wild-type controls (age- and sex-matched control group, CG). Short- and long-term outcomes were reported for the SG. Short-term outcomes were compared between the two groups. Seventy patients were screened for MC4R-d. The SG [six individuals (four females, two males); 18 (10-27) years old at BS; 50.3 (41.8-61.9) kg/m Our data indicate efficacious short-term but varied long-term weight loss and glycemic control outcomes of BS on patients with MC4R-d, suggesting the importance of ongoing monitoring and complementary therapeutic interventions. Show less